- Home
- Software Solutions
- Resources
- Corporate
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain
Sponsors:
| Phases:
| |
| Indications | Acronym: Alchemilla | |
| ||
Age Groups:
| Gender: Both | |
Names:
| Enrollment: 198 | |
Additional information about NCT01463397.